Cardiovascular Safety The SELECT trial evaluating cardiovascular outcomes in patients with obesity and established cardiovascular disease demonstrated that serious adverse events were actually lower with semaglutide versus placebo (33.4% vs 36.4%), primarily driven by fewer cardiac disorders (11.5% vs 13.5%)
In aged Rhesus monkeys, Epitalon treatment stimulated melatonin production and restored youthful secretion patterns, while also normalizing cortisol rhythms in a time-of-daydependent manner [59]
overcame a step therapy denial for Ozempic by documenting severe gastrointestinal side effects from required first-line medications
The limitations of this work are that we included RCTs, non-RCTs, and observational studies, which may lower the overall quality of evidence of the included studies
In cases where an employer is providing plan coverage for GLP-1 medications for obesity, there are risks and potential unforeseen consequences if the coverage doesnt have a defined plan structure and a managed process for treatment
Amer J Epidem
